Losartan Potassium
Product Images NDC 53002-3643

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53002-3643). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530023643)

Losartan Potassium 50 mg tablets packaging label from RPK Pharmaceuticals, Inc. The label indicates a bottle with 100 tablets and instructs to take 1 tablet daily or as directed. Includes prescription information, use instructions, and space for dispensing and prescriber details. The NDC number 53002-3643 appears on the label.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with a primary endpoint over 66 months of study between Losartan Potassium and Atenolol. The graph shows adjusted risk reduction percentage and a statistical significance p-value, illustrating comparative efficacy in a clinical study.*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 months of study between Atenolol and Losartan Potassium. The graph indicates adjusted risk reduction of 25% for Losartan Potassium, with corresponding p-value of 0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

A figure titled 'Primary Endpoint Events within Demographic Subgroups' comparing event rates and hazard ratios of Losartan Potassium versus Atenolol across different demographic categories. The chart includes two parts: Primary Composite events and Stroke (Fatal/Non-fatal) events, showing numerical data, confidence intervals, and hazard ratio plots for age, gender, race, ISH, diabetes, and history of cardiovascular disease.*

FDA Label Image

Figure-4 (Losartan Fig4)

A Kaplan-Meier curve comparing the percentage of patients with an event over 48 months between two groups: Losartan Potassium (solid line) and placebo (dashed line). The chart indicates a risk reduction of 16.1% with Losartan Potassium and a p-value of 0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of Losartan Potassium showing its molecular arrangement with a potassium ion (K+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.